NOVAVAX INC Cash and Cash Equivalents, Period Increase (Decrease)
NOVAVAX INC (NVAX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$38.05 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-14.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-14
- NOVAVAX INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $2.06M, a 91.55% decline year-over-year.
- NOVAVAX INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $28.45M, a 6.88% decline year-over-year.
- NOVAVAX INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$20.05M.
- NOVAVAX INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$48.51M, a 224.00% decline year-over-year.
- NOVAVAX INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$38.05M, a 174.24% decline from fiscal 2016.
- NOVAVAX INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was $51.24M, a 15.68% decline from fiscal 2015.
- NOVAVAX INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was $60.77M.
- NOVAVAX INC cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$87.14M, a 185.37% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $30.51M derived: sum of 2 quarters · filed 2018-03-14 | $10.46M derived: sum of 3 quarters · filed 2018-03-14 | -$38.05M 10-K · filed 2018-03-14 |
| 2017-09-30 | $28.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $8.40M derived: sum of 2 quarters · filed 2017-11-07 | -$40.11M 10-Q · filed 2017-11-07 | -$15.70M derived: sum of 4 quarters · filed 2018-03-14 |
| 2017-06-30 | -$20.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$68.56M 10-Q · filed 2017-08-08 | -$44.16M derived: sum of 3 quarters · filed 2018-03-14 | -$13.60M derived: sum of 4 quarters · filed 2018-03-14 |
| 2017-03-31 | -$48.51M 10-Q · filed 2017-05-08 | -$24.10M derived: sum of 2 quarters · filed 2018-03-14 | $6.45M derived: sum of 3 quarters · filed 2018-03-14 | -$36.38M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-12-31 | $24.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $54.96M derived: sum of 2 quarters · filed 2018-03-14 | $12.13M derived: sum of 3 quarters · filed 2018-03-14 | $51.24M 10-K · filed 2018-03-14 |
| 2016-09-30 | $30.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$12.28M derived: sum of 2 quarters · filed 2017-11-07 | $26.84M 10-Q · filed 2017-11-07 | -$18.20M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | -$42.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$3.71M 10-Q · filed 2017-08-08 | -$48.75M derived: sum of 3 quarters · filed 2018-03-14 | -$77.99M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $39.12M 10-Q · filed 2017-05-08 | -$5.92M derived: sum of 2 quarters · filed 2018-03-14 | -$35.16M derived: sum of 3 quarters · filed 2018-03-14 | -$82.83M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | -$45.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$74.28M derived: sum of 2 quarters · filed 2018-03-14 | -$121.94M derived: sum of 3 quarters · filed 2018-03-14 | $60.77M 10-K · filed 2018-03-14 |
| 2015-09-30 | -$29.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$76.91M derived: sum of 2 quarters · filed 2016-11-09 | $105.81M 10-Q · filed 2016-11-09 | $103.67M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | -$47.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $135.05M 10-Q · filed 2016-08-09 | $132.91M derived: sum of 3 quarters · filed 2017-02-27 | $63.53M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $182.72M 10-Q · filed 2016-05-05 | $180.58M derived: sum of 2 quarters · filed 2017-02-27 | $111.19M derived: sum of 3 quarters · filed 2017-02-27 | $105.13M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | -$2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$71.52M derived: sum of 2 quarters · filed 2017-02-27 | -$77.59M derived: sum of 3 quarters · filed 2017-02-27 | -$87.14M 10-K · filed 2017-02-27 |
| 2014-09-30 | -$69.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$75.45M derived: sum of 2 quarters · filed 2015-11-09 | -$85.00M 10-Q · filed 2015-11-09 | -$88.02M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$6.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$15.61M 10-Q · filed 2015-08-10 | -$18.64M derived: sum of 3 quarters · filed 2016-02-29 | $101.28M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$9.55M 10-Q · filed 2015-05-07 | -$12.57M derived: sum of 2 quarters · filed 2016-02-29 | $107.35M derived: sum of 3 quarters · filed 2016-02-29 | $100.90M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $116.90M derived: sum of 2 quarters · filed 2016-02-29 | $110.45M derived: sum of 3 quarters · filed 2016-02-29 | $102.07M 10-K · filed 2016-02-29 |
| 2013-09-30 | $119.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $113.47M derived: sum of 2 quarters · filed 2014-11-06 | $105.09M 10-Q · filed 2014-11-06 | $111.75M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | -$6.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$14.82M 10-Q · filed 2014-08-07 | -$8.16M derived: sum of 3 quarters · filed 2015-02-27 | -$12.76M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | -$8.38M 10-Q · filed 2014-05-08 | -$1.72M derived: sum of 2 quarters · filed 2015-02-27 | -$6.31M derived: sum of 3 quarters · filed 2015-02-27 | -$4.85M derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $2.06M derived: sum of 2 quarters · filed 2015-02-27 | $3.53M derived: sum of 3 quarters · filed 2015-02-27 | $3.29M 10-K · filed 2015-02-27 |
| 2012-09-30 | -$4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$3.13M derived: sum of 2 quarters · filed 2013-11-12 | -$3.37M 10-Q · filed 2013-11-12 | -$3.58M derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-06-30 | $1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $1.23M 10-Q · filed 2013-08-08 | $1.02M derived: sum of 3 quarters · filed 2014-03-12 | $2.24M derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-03-31 | -$231.00K 10-Q · filed 2013-05-09 | -$445.00K derived: sum of 2 quarters · filed 2014-03-12 | $781.00K derived: sum of 3 quarters · filed 2014-03-12 | $5.51M derived: sum of 4 quarters · filed 2014-03-12 |
| 2011-12-31 | -$214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $1.01M derived: sum of 2 quarters · filed 2014-03-12 | $5.75M derived: sum of 3 quarters · filed 2014-03-12 | $6.04M 10-K · filed 2014-03-12 |
| 2011-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $5.96M derived: sum of 2 quarters · filed 2012-11-09 | $6.26M 10-Q · filed 2012-11-09 | -$1.90M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $4.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $5.03M 10-Q · filed 2012-08-09 | -$3.12M derived: sum of 3 quarters · filed 2013-03-12 | $3.65M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $297.00K 10-Q · filed 2012-05-09 | -$7.86M derived: sum of 2 quarters · filed 2013-03-12 | -$1.09M derived: sum of 3 quarters · filed 2013-03-12 | |
| 2010-12-31 | -$8.15M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$1.39M derived: sum of 2 quarters · filed 2013-03-12 | -$30.70M 10-K · filed 2013-03-12 | |
| 2010-09-30 | $6.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | -$22.54M 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | -$29.31M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $11.82M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |